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ABSTRACT 
XIAOMEI GU: Physiopathology of Osteoclast in Bone  
(Under the direction of Dr. Eric T. Everett) 
 
  Bone is constantly remodeled by osteoclastic bone resorption and osteoblastic bone 
formation. Abnormal remodeling can result in bone mass change; bone loss is implicated in 
a number of bone diseases, representing an increase in bone resorption relative to formation. 
Therefore, an understanding of osteoclast biology is important to demystify the 
pathogenesis of bone diseases and to develop treatment strategies. Osteoclasts are formed 
by fusion of hematopoietic monocyte/macrophage lineage cells, in which 
osteoblasts/stromal cells play a central role by producing macrophage-colony stimulating 
factor and receptor activator of nuclear factor κ B ligand. Characterization of 
osteoclastogenesis has provided new insight into our understanding of bone diseases with 
excessive bone resorption. Moreover, anti-resorptive drugs, bisphosphonates, have been 
developed to target osteoclasts and their function. Additionally, a better understanding of 
the interactions of fluoride between osteoclasts may help harness the desirable effects of 
fluoride on bone while limiting its undesirable effects.  
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CHAPTER I. BASIC BONE BIOLOGY 
 
 
1.1. Thesis Introduction 
  Regardless of etiologies, bone loss represents an increase in bone resorption by 
osteoclasts relative to bone formation by osteoblasts. Understanding osteoclast biology and 
bone resorption are essential in understanding the pathogeneses and therapies of diseases 
involving excessive bone destruction. This thesis will begin with a very brief introduction of 
basic bone biology to orient the readers’ understanding of osteoclasts in a context of normal 
bone remodeling. In the subsequent two chapters, origin, differentiation, and function of 
osteoclasts will be addressed in greater detail. To help understand osteoclast differentiation 
and its regulation, the role of osteoclast formation in periprosthetic osteolysis, 
peri-implantitis, and orthodontic tooth movement will also be discussed. In addition to the 
mechanism of bone resorption, this thesis will also explore two newly-identified functions of 
osteoclasts: mobilizing hematopoietic stem cells in bone marrow and stimulating osteoblastic 
bone formation.  
  Osteoclastic bone resorption has been implicated in a number of diseases; however, 
this thesis will primarily focus on the cellular and molecular pathogenesis of common 
metabolic bone disease, such as osteoporosis and Paget’s disease of bone. Parathyroid 
hormone (PTH) plays a central role in calcium homeostasis via its action on targeting tissues 
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such as bone cells [1, 2]. The anabolic action of PTH will be discussed in a context of 
osteoclasts being the anabolic signaling sources (Chapter III), whereas the catabolic action of 
PTH will be discussed in a context of hyperthyroidism pathogenesis. The recent 
breakthrough in understanding the pathogenesis of a genetic disorder, Cherubism, is a good 
example of how understanding osteoclast biology can advance our understanding of a disease 
process.  
  Osteoclasts are the primary therapeutic targets for conditions with excessive bone 
resorption. Bisphosphonate is a major class of anti-resorptive drug currently available. In 
the last chapter, this thesis will discuss the actions of bisphosphonates on bone with a focus 
on their induction of osteoclast apoptosis. Meanwhile, the actions of fluoride on bone cells 
will also be addressed. The anabolic action of fluoride on bone has been largely explained 
by its mitogenic effect on osteoblasts; however, this thesis will mainly focus on the effects 
of fluoride on osteoclasts. A complete picture of fluoride’s effects on the two major cell 
types in bone—osteoblasts and osteoclasts—is required for the utilization and/or 
optimization of fluoride’s potential in treating diseases with excessive bon resorption. By 
reviewing the pathophysiology of osteoclasts, this thesis will provide a powerful context to 
better understand fluoride’s effect on osteoclasts. 
 
1.2. Embryonic Development of Bone 
  The skeletal system develops from three distinct origins: 1) the paraxial mesoderm 
gives rise to the axial skeleton (vertebrae and ribs); 2) the lateral plate mesoderm gives rise to 
the appendicular skeleton (limb skeleton); and 3) the cranial neural crest, which is derived 
from the ectoderm, gives rise to the craniofacial skeleton [3].  
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  Bone development occurs through two distinct developmental processes:  
intramembranous ossification and endochondral ossification.  During intramembranous 
ossification, mesenchymal cells condense and differentiate directly into osteoblasts to lay 
down bone matrix [4]. This process occurs in several craniofacial bones and the lateral part of 
clavicles [5]. During endochondral ossification, mesenchymal cells condense and 
differentiate directly into chondroblasts to synthesize a cartilage model, which is then 
replaced by bone and bone marrow [4]. This process occurs in the long bones of the limbs, 
basal part of the skull, vertebrae, ribs, and medial part of the clavicles [5]. Therefore, the 
major difference between the two types of ossification is the presence of a cartilaginous 
precursor template during endochondral ossification.  
 
1.3. Bone Function 
  Bone tissue has the following functions: 1) it provides structural support for the 
body; 2) it protects internal organs, such as brain, spinal cord, heart, and lungs; 3) it supports 
hematopoiesis in bone marrow; 4) it is the basis of posture and locomotion by allowing the 
attachments of muscles, ligaments, and tendons; 4) it serves as a mineral reservoir and in 
particular helps regulate calcium homeostasis [6, 7]. 
 
1.4. Components of Bone 
  As in all connective tissues, the fundamental constituents of bone are cells and 
extracelluar matrix. However, unlike most of other tissues, the extracelluar matrix of bone is 
mineralized by calcium salts in form of hydroxyapatite, which provides stiffness to the 
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tissue. The organic matrix is largely composed of type I collagen (95%), and the remaining 
5% is composed of proteoglycans and numerous non-collagenous proteins [4, 8]. Three 
major cell types are present in bone tissue: osteoblasts, osteocytes, and osteoclasts [4].   
 
1.4.1. Osteoblasts 
  Osteoblasts are the cells responsible for bone formation [7]. They are derived from 
mesenchymal stem cells in bone marrow [11]. Under appropriate stimuli, these multipotent 
cells can differentiate along three principal lineages: osteoblastic, adipocytic and 
chondrocytic lineages [6, 12]. Expression of the transcription factors, runt-related 
transcription factor-2 (Runx2), is required to shift the progenitors toward the osteoblast 
lineage and away from adipocytic and chondrocytic lineages. Further differentiation of the 
preosteoblast into a mature, functional osteoblast phenotype requires the expression of 
another transcription factor, osterix (Osx). The early stage of osteoblastic differentiation is 
characterized by markers such as type I collagen and alkaline phosphatase (ALP), while the 
late stage of osteoblastic differentiation is characterized by markers, such as osteoclacin and 
mineralization of extracellular matrix [5, 6].  
  Mature and active osteoblasts synthesize most of the proteins in bone extracellular 
matrix [6, 7]. Some osteoblasts are buried in bone matrix and become osteocytes, while some 
osteoblasts become flattened cell on bone surface—bone-lining cells (inactive osteoblasts) 
[7].  
  Besides the bone-forming function, osteoblasts provide essential signals for 
osteoclast differentiation and its regulation (discussed in more detail in Chapter II) [13]. 
Moreover, recent studies have found that osteoblasts also play a central role in hematopoiesis 
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by providing many factors essential for the survival, renewal, maturation and lineage 
commitment of hematopoietic stem cells [14, 15]. 
 
1.4.2. Osteocytes 
  Osteocytes are the most abundant cells in bone (25,000/mm3 of bone [4]) and yet 
remain the least characterized [16]. They are terminally differentiated osteoblasts that have 
become entombed in bone matrix [7, 16]. Osteocytes are strain-sensitive and can transduce 
mechanical signals. Recent studies have shown that damage-induced osteocyte apoptosis 
may be involved in the recruitment of osteoclasts and initiation of new bone remodeling [16, 
17].  
 
1.4.3. Osteoclasts 
  Osteoclasts are cells that can resorb bone [18]. They are of hematopoietic origin, and 
are formed by the maturation and fusion of monocyte/macrophage lineage common 
precursors [19]. Mature osteoclasts are large, multi-nuclear cells and have morphology 
highly specialized for its bone-resorbing function [20]. After fulfilling the resorption 
function, they are likely to be removed by apoptosis [21]. The biology and physiopathology 
of osteoclasts will be discussed in more detail in the following chapters of this thesis.  
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1.5. Bone Structure: Cortical Bone and Trabecular Bone 
  Morphologically, there are two major forms of bone: cortical (compact) and 
trabecular (cancellous or spongy). In cortical bone, collagen fibrils are densely arranged to 
form concentric lamellae, with fibrils assembled in perpendicular planes in adjacent lamellae. 
Trabecular bone is composed of a porous network of thin and mineralized trabeculae with 
lamellae arranged parallel to each other [4, 8]. The percentage of cortical and cancellous bone 
varies among different sites in the skeletons system. For example, in the lumbar spine, 66% 
of the bone is cancellous bone, whereas in the midradius >95% of the bone is cortical bone 
[4].  
 
1.6. Bone Histology: Lamellar Bone and Woven Bone 
  Bone can also be classified as lamellar bone and woven bone. Lamellar bone is 
mature bone, in which the collagen fibers are arranged in a lamellar structure [9, 10]. 
Lamellar bone is mainly composed of cylindrical units called osteons or Haversian systems, 
which consist of a central canal surrounded by concentric lamellae. The central canal is called 
osteonal or Haversian canal and contains blood vessels and nerves [10]. Woven bone is 
immature bone, which is formed very rapidly during skeletagenesis or fracture healing. The 
collagen fibers in woven bone are loosely arranged in irregular arrays and woven bone is 
therefore also called nonlamellar bone. Woven bone contains more cells per unit area than 
lamellar bone [9]. 
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1.7. Bone Remodeling 
  Although it appears to be inert and static, bone tissue is metabolically active. 
Throughout life, bone is constantly broken down and rebuilt; this continuous process of bone 
resorption and bone formation is called bone remodeling [6].  
 
1.7.1. Purposes of Bone Remodeling 
  It has been generally accepted that bone remodeling serves two closely linked 
purposes. First, some remodeling can be directed towards specific sites to repair fatigue 
damage, continuously replacing fatigued bone with mechanically competent new bone. So 
bone remodeling is necessary to maintain the mechanical strength and structural integrity of 
new bone. Secondly, through continuous bone resorption and formation, bone subserves its 
metabolic functions as a storehouse of calcium and phosphorus. Therefore, bone remodeling 
plays a very important role in maintaining mineral homeostasis [22, 23].  
 
1.7.2. Cellular Processes of Bone Remodeling 
  Bone-resorbing osteoclasts and bone-forming osteoblasts work as a team to 
remodel bone. At the microscopic level, bone remodeling occurs in small areas of the cortical 
and trabecular surface, known as basic multicellular units (BMUs) [24, 25]. At each BMU, 
resorption always precedes formation. Osteoclasts remove a certain amount of bone, and 
osteoblasts subsequently deposit organic matrix and mineral to fill the previously created 
cavity [25]. Therefore, bone remodeling involves sequential activities of two distinct cell 
types in bone.  
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1.7.3. Difference between Bone Remodeling and Bone Modeling 
  During bone remodeling, bone resorption is always followed by bone formation at 
a locus, and these two processes are said to be coupled to one another [17]. In fact, it is the 
coupling of osteoclast activity to osteoblast activity that makes bone remodeling distinctive 
from bone modeling. Bone modeling refers to a process in which bone are shaped or 
reshaped by the independent activities of osteoclasts and osteoblasts [17]. Therefore, unlike 
remodeling, bone modeling at a single site involves either bone resorption or bone 
formation, but not both. Bone modeling is most pronounced during bone growth and 
development; it also occurs in adults bone in response to mechanical loads [17, 22].  
 
1.7.4. Regulation of Bone Remodeling  
   Bone remodeling process is highly regulated by numerous local factors and 
systemic hormones. These factors include bone morphogenetic protein (BMP), tumor growth 
factor β (TGFβ),  tumor necrosis factor α (TNFα),  interleukins, estrogen, prostaglandin E2 ( 
PGE2), parathyroid hormone (PTH), calcitonin, and vitamin D [25]. Among them, estrogen is 
considered the most important hormone in maintaining normal bone turnover [26]. It has a 
dual effect on bone remodeling: on one hand, it can increase bone formation; on the other 
hand, it can reduce bone resorption [25]. 
  The delicate balance between bone resorption and bone formation is essential for the 
maintenance of normal bone functions. Imbalance between the two can result in 
compromised bone renewal and change in bone mass; skeletal diseases will develop. 
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Increased bone resorption or a relative decrease in bone formation compared to bone 
resorption can lead to osteoporosis (osteoporosis will be further discussed in Chapter IV). In 
contrast, increased bone formation or a relative decrease in bone resorption compared to bone 
formation can lead to osteopetrosis [6].  
 
1.8. Chapter Summary 
  Bone is a highly specialized connective tissue. It consists of mineralized extracelluar 
matrix and three major cell types—the bone-forming osteoblast, the bone-resorbing 
osteoclast, and the osteocyte. To carry out its functions, bone undergoes constant remodeling 
throughout life. Bone remodeling is carried out by the coupled activities of osteoclasts and 
osteoblasts. The balance between bone resorption and bone formation is very important for 
normal bone function. Disruption of this balance will lead to metabolic bone diseases. 
Therefore, understanding the normal process of bone remodeling will allow us to better 
understand the pathogenesis of metabolic bone diseases. 
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CHAPTER II. OSTEOCLAST BIOLOGY: ORIGIN AND 
DIFFERENTIATION  
 
 
  Osteoclasts are the exclusive bone resorptive cells. They are large, multinucleated, 
and terminally differentiated cells formed via the fusion of their mononuclear precursors [1]. 
 
2.1. Osteoclast Origin 
  Controversy concerning the origin of osteoclasts existed until the late 1970s. The 
pioneering parabiosis experiments where the circulation of a normal rat was connected to an 
irradiated rat have demonstrated that cells able to differentiate to osteoclasts were present in 
the circulation and can be recruited to bone-resorbing sites via the blood stream [2]. This 
observation was further corroborated by studies using osteopetrotic mouse models. The 
osteopetrotic phenotype of these mice can be rescued after parabiotic union to normal mice, 
or after transplantation of bone marrow cells from normal mice [2, 3]. The cure of 
osteopetrosis by bone marrow transplantation has also been established in humans [4]. It is 
widely accepted that the osteoclast is of hematopoietic origin [2].  
  Subsequently, it has been shown that the osteoclast precursor belongs to the 
monocyte/macrophage family derived from the myeloid progenitors [2, 5-7]. Hematopoietic 
 13
stem cells (HSCs) generate all the blood cell types, including the lymphoid and myeloid 
lineages. The determination of HSCs to the myeloid lineage requires the expression of the 
transcription factor PU.1 [8, 9]. The myeloid lineage, also known as colony forming 
unit-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM), gives rise to 
CFU-GM (granulocyte, monocyte/macrophage), and CFU-M (monocyte/macrophage), the 
latter being the common precursors of osteoclasts and macrophages (Figure 2.1.) [3,10]. 
Interestingly, compared to the more committed CFU-M-derived cells, CFU-GM-derived 
cells have greater osteoclast differentiating potential in in vitro mouse and human studies [11, 
12]. Nevertheless, it has been generally accepted that osteoclasts are derived from CFU-M, 
the monocyte/macrophage lineage [4].  
  Even though osteoclasts can be generated in vitro from mononuclear phagocytes of 
various tissues, osteoclast precursors primarily reside in bone marrow [4, 5, 13]. The 
formation of osteoclasts only occurs in the close vicinity of bone, and multinucleated 
osteoclasts are not present in the circulation [13].   
 
2.2. Osteoclast Differentiation 
  It was first proposed in 1981 that osteoblasts were involved in osteoclast 
differentiation [2]. After almost 10 years, a co-culture system of mouse osteoblasts/stromal 
cells and hematopoietic cells for osteoclast formation (or osteoclastogenesis) established the 
concept that osteoblast/stromal cells are essentially involved in the formation of osteoclasts. 
The close contact between cells from the osteoblastic and hematopoietic lineage is necessary 
for osteoclastogenesis [2]. It is now known that stromal cells/osteoblasts are able to produce 
two essential factors for osteoclastogenesis: nuclear factor (NF)κB ligand (RANKL) and 
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macrophage colony-stimulating factor (M-CSF) [7, 10]. Signaling pathways initiated by 
these two factors lead to the expression of genes typifying osteoclasts [7, 10]. Mature 
osteoclasts are characterized by markers such as integrin αVβ3, calcitonin receptor (CTR), 
cathepsin K (CTK), metalloproteinase-9 (MMP-9), H+-ATPase, and tartrate resistant alkaline 
phosphatase (TRAP) (Figure 2.1.) [2].  
 
2.2.1. Role of M-CSF in Osteoclast Differentiation 
  M-CSF, also known as colony-stimulating factor-1 (CSF-1), was the first 
colony-stimulating factor to be purified [14]. It was formerly known as macrophage growth 
factor (MGF) or macrophage and granulocyte inducer IM (MGI-IM) [14]. M-CSF is a 
homodimeric glycoprotein synthesized constitutively by bone marrow stromal cells and 
osteoblasts [14-16]. It induces proliferation and survival of the common precursors of 
osteoclasts and macrophages. Additionally, M-CSF signaling stimulates RANK expression 
in osteoclast precursors, rendering them more responsive to RANKL [16-18]. The pivotal 
role of M-CSF in osteoclastogenesis has been confirmed by studies of osteopetrotic (op/op) 
mice. These mice harbor a null mutation in the coding region of M-CSF gene, which leads to 
the production of a truncated protein. The biologically inactive M-CSF leads to a severe 
deficiency in osteoclast formation and hence osteopetrotic phenotypes. Moreover, many of 
the effects of the op/op mutation can be rescued by the administration of soluble M-CSF to 
neonatal mice [19].  
  The biological effects of M-CSF are mediated via its sole receptor, c-fms, which is 
also referred to as CSF-1R or M-CSFR [14-16]. The transcription factor PU.1 binds to the 
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promoter region of c-fms gene and positively regulates its transcription [15]. Mice deficient 
in PU.1 exhibit an osteopetrotic phenotype similar to the op/op mice [9]. c-fms is a member 
of the class III receptor tyrosine kinase family and is encoded by the proto-oncogene c-fms  
(also known as csf1r). It is an integral plasma membrane glycoprotein, expressed primarily 
on macrophages and osteoclasts [14-16]. The functional linkage between M-CSF and c-fms 
has been established by the observation that mice lacking c-fms gene exhibit the same major 
osteopetrotic phenotypes as op/op mice [16, 18]. 
  The binding of M-CSF to c-fms results in the dimerization and the 
auto-phosphorylation of c-fms. This leads to the recruitment of c-Src kinase, which then 
phosphorylates the adaptor protein, c-Cbl. c-Cbl recruits a multiprotein complex containing 
growth-factor-receptor-bound protein 2 (Grb2) and phosphoinositide 3-kinase (PI3K), with 
the former activating extracellular-signal-regulated kinase (ERK) and the latter the 
serine/threonine kinase AKT (or protein kinase B, PKB) (Figure 2.2.) [16, 18, 20]. 
Collectively, M-CSF induces the proliferation of osteoclast precursor cells and supports their 
survival through PI3K /AKT and Grb2/ERK axis.  
 
2.2.2. Role of RANKL in Osteoclast Differentiation  
  RANKL, a type II (carboxy-terminal outside the cell) membrane protein, belongs to 
the tumor necrosis factor (TNF) superfamily [21-24]. It is also known by the following 
names: TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand 
(OPGL), tumor necrosis factor (ligand) superfamily member 11 (Tnfsf11), and osteoclast 
differentiation factor (ODF) [24, 25]. RANKL is extensively expressed on the plasma 
membrane of osteoblasts/stromal cells [24, 25]. It has been shown to be proteolytically 
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released from the cell surface by the metalloproteasedisintegrin TNF α convertase (TACE) 
[26, 27]. In the presence of M-CSF, both membrane-bound and soluble RANKL can support 
osteoclast differentiation in vitro [25]. However, the membrane-bound may be more efficient 
than the soluble form [26]. The in vivo biological and pathological significance of soluble 
RANKL still remains unclear. The importance of RANKL in osteoclast formation has been 
collaborated by animal studies. RANKL−/− mice display complete failure of 
osteoclastogenesis and consequently develop severe osteopetrosis [24, 28].   
  The receptor for RANKL—RANK (receptor activator of NFκB)—is a type I 
membrane protein and belongs to the TNF receptor superfamily [25]. RANK is also known 
as TRANCE-R or TNFRSF11A, and is expressed as a transmembrane heterotrimer on the 
surface of osteoclasts and their precursors [24, 25]. Mice lacking rank have exactly the same 
osteopetrotic phenotype as rankl−/−mice. However, rank−/− mice have an intrinsic defect in 
osteoclasts as indicated by the fact that their phenotype can be reversed by bone marrow 
transplantation from normal mice [25, 29].  
   When RANK on osteoclasts is recognized by RANKL, it sends signals into the cells 
through adapter proteins (Figure 2.2.). Like other TNF receptor superfamily member 
proteins, the intracellular domain of RANK directly binds to TRAF6 (TNF receptor 
associated factor 6), which undergoes trimerization and then activates the NF-κB, Akt, and 
mitogen-activated protein kinases (MAPKs) pathways (Figure 2.2.) [24, 25, 30]. Meanwhile, 
RANKL induces the expression of c-Fos, which, in turn, activates the transcription factor 
complex, AP1 (activator protein 1) [31-33]. The common target gene of NF-κB and AP-1 has 
been recently shown to be NFATc1 (nuclear factor of activated T cells, cytoplasmic 1) [31, 
34, 35]. NFATc1, a member of the NFAT family of transcription factor genes, is considered 
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to be the master transcription factor for osteoclastogenesis since its induction activates the 
expression of osteoclast-specific genes [32, 33, 36]. Genetics studies have shown that 
osteopetrosis occurs in mice lacking key genes involved in RANKL signaling, such as 
TRAP6 and c-Fos [37-39].  
 
2.2.3. Costimulatory Signals for RANK 
  Since authentic osteoclasts can be generated in vitro from bone marrow cells in 
response to recombinant RANKL and M-CSF, it has been generally accepted that RANKL 
and M-CSF signaling is not only necessary but also sufficient to support osteoclastogenesis 
[40, 41]. However, recent studies have revealed a more complex picture: additional 
costimulatory signals are required to activate the transcription factor, NFATc1 [32, 33, 36, 
42].  
  Through interaction between complementarily charged amino acid residues, 
transmembrane adaptor proteins (e.g. FcRγ and DAP12) associate with immunoglobulin-like 
receptors (e.g. OSCAR, PIR-A, TREM-2, and SIRPβ1) [32, 33, 36]. Following the 
stimulation of immunoglobulin-like receptors likely by endogenous ligands from osteoclast 
precursors or stromal cells/osteoblasts and RANKL-initiated signaling, the ITAM motifs 
present in those adaptor proteins are phosphorylated. This leads to the recruitment of the Syk 
family kinase to the phosphorylated tyrosine residues [32]. Consequently, the calcium 
signaling pathway is activated through phospholipase Cγ (PLCγ), followed by induction of 
NFATc1 (Figure 2.3.) [32, 33, 36]. Moreover, DAP12−/−FcRγ−/− mice exhibit severe 
osteopetrosis due to defective osteoclast differentiation, and the retroviral transfer of normal 
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DAP12 into DAP12−/−FcRγ−/− cells can rescue osteoclast differentiation deficiency [33]. 
These data indicate that ITAM signaling is indispensable for RANKL-induced 
osteoclastogenesis. However, so far it still remains largely unknown how RANKL/RANK 
signaling synergizes with ITAM signaling.   
 
2.3. Regulation of Osteoclast Differentiation 
  Osteoclast differentiation is subject to negative and positive regulation by 
circulating hormones and locally produced cytokines [4, 43]. Major mechanisms underlying 
the regulation of osteoclast differentiation are discussed in the following sections.  
 
2.3.1. The OPG/RANKL/RANK Regulatory Axis 
  OPG (osteoprotegerin, i.e. protector of bone), also known as osteoclastogenesis 
inhibitory factor (OCIF), is a secreted protein expressed by osteoblasts/stromal cells [44-46]. 
OPG, like RANK, belongs to the TNF receptor superfamily. However, in contrast to all other 
members, OPG lacks transmembrane and cytoplasmic domains and is secreted as a soluble 
protein. OPG functions as a soluble decoy receptor to RANKL, competing with RANK for 
RANKL binding (Figure 2.4.) [41, 46, 47]. OPG is a negatively regulator of RANKL 
activity. Genetic studies have found that excessive RANKL activity, as in OPG deficient 
mice, results in early-onset osteoporosis [48, 49]. In contrast, due to a decreased net RANKL 
level, transgenic mice overexpressing OPG exhibit osteopetrosis [46].  
  Studies have shown that the balance between RANKL/RANK and OPG levels 
regulate osteoclast differentiation and bone metabolism [46, 50]. Most hormones and 
cytokines inhibit or enhance bone resorption via osteoblasts/stromal cells, regulating their 
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expression of RANKL and OPG (see reference [46] for a thorough list) [4, 43, 46, 47]. For 
example, TGF-β released from bone matrix during bone resorption has been shown to 
upregulate OPG expression, serving as a negative feedback mechanism for bone resorption 
[24, 26]. Interleukins (IL-1, 6, 11, and 17) can increase RANKL expression [24, 25, 46]. 
Some factors not only decrease OPG expression but also increase RANKL expression, such 
as parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), and 
prostaglandin E2 (PGE2) [25, 46]. Dexamethasone and 25-dihydroxy vitamin D3 (1, 
25(OH)2D3, the active form of vitamin D3) can stimulate RANKL production and are often 
used in coculture of bone marrow cells and stromal cells to generate osteoclasts in vitro [25, 
46]. Therefore, the OPG/RANKL/RANK axis is critical for maintaining the balance between 
bone formation and resorption by providing a means for controlling osteoblast and osteoclast 
activity (Figure 2.4.).  
   
2.3.2. Other Regulatory Mechanisms 
  In addition to the OPG/RANKL/RANK regulatory system, recent studies have 
shown that other local molecules produced by osteoblasts/stromal cells and immune cells can 
enhance or inhibit osteoclast formation [51, 52]. Secreted frizzled-related protein 1 (sFRP1), 
an inhibitor of the Wnt signaling pathway, is expressed by osteoblasts/stromal cells [51], and 
directly inhibits osteoclast formation by binding to RANKL in vitro [53]. Osteoclast 
inhibitory lectin (OCIL) is a membrane-bound lectin expressed by osteoblasts, and its soluble 
form can inhibit osteoclast formation in vitro [54]. Aside from osteoblasts/stromal cells, other 
cell types are also involved in osteoclastogenesis regulation [50, 55]. In vitro studies have 
suggested that through an unknown mechanism, megakaryocytes can inhibit osteoclast 
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formation [56]. Taken together, more studies, especially in vivo ones, are necessary to further 
explore other mechanisms that regulate osteoclast differentiation.  
 
2.4. Osteoclast Fusion  
  During osteoclastogenesis, preosteoclasts fuse to form multinuclear mature 
osteoclasts. Studies comparing the gene expression of multinuclear osteoclasts and 
mononuclear macrophages have identified two molecules critically involved in cell–cell 
fusion of osteoclasts: the dendritic cell-specific transmembrane protein (DC-STAMP) [57, 
58] and the d2 isoform of vacuolar H+-ATPase V0 domain (Atp6v0d2) [59]. Mice deficient in 
either DC-STAMP or Atp6v0d2 lack multinuclear osteoclasts and develop osteopetrosis 
[57-59]. Further studies have demonstrated that the expression of DC-STAMP and Atp6v0d2 
are induced by transcription factor, NFATc1 [60, 61]. Interestingly, a recent study has 
suggested a newly-identified protein induced by RANKL, osteoclast stimulatory 
transmembrane protein (OC-STAMP), is required in the fusion process during 
osteoclastogenesis [62]. It appears that multiple factors are involved in osteoclast fusion, and 
more studies are necessary to further understand this process.  
 
2.5. Osteoclasts in Periprosthetic Osteolysis and Peri-implantitis 
  Studies have shown that osteoclasts play a key role in periprosthetic osteolysis, one 
of the major complications of orthopaedic replacement [63]. Particulate wear debris 
generated by bearing surfaces has been identified as a major contributory component in 
osteolysis [64-67]. However, the mechanism by which particles induce cellular response and 
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subsequent osteolysis is largely unclear. The primary cellular response to implants is the 
phagocytosis of foreign particles, which somehow activates macrophages to release 
numerous pro-inflammatory cytokines, including TNFα, IL-1α, IL-1β, IL-6, and PGE2 [64, 
68, 69]. These cytokines may explain, at least partially, the increased levels of RANKL and 
RANK in the interface tissue in loosening orthopaedic replacement, leading to increased 
osteoclastogenesis and bone resorption [64, 70, 71]. In addition to the RANK/RANKL 
signaling pathway, some cytokines, especially TNFα, may enhance osteoclast differentiation 
directly [70]. 
  In addition to the involvement of the macrophage-mediated foreign body immune 
response to particles, T lymphocytes may also play an important role in periprosthetic 
osteolysis [72, 73]. Immunohistochemical studies have found a large number of T cells in 
osteolytic tissues [73]. The interplay of immune system and bone has been well established. 
Activated T cells are well known to produce RANKL and thus directly support 
osteoclastogenesis [52, 74]. T cells can also produce other osteoclastogenic factors, further 
contributing to the process of the bone destruction in inflammatory conditions such as 
rheumatoid arthritis [75]. Whether T cells in osteolytic tissues can secrete other cytokines to 
influence the RANKL/RANK/OPG system remained to be defined. Collectively, excessive 
osteoclastogenesis and bone resorption caused by the imbalance of RANKL/RANK/OPG 
axis plays an important role in aseptic loosening [64, 70, 71].  
  Similarly, osteoclasts are also involved in the interface of bone and dental implants 
[76]. It has been proposed that dental implants can induce production of osteoclastogenic 
cytokines such as TNFα and IL-1β in peri-implant tissue, resulting in implant failing [76, 77]. 
Immunohistochemical studies have shown that the expression of TNFα, IL-1α, and IL-6 is 
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significantly increased in peri-implant tissue from loosened implants [77]. In order to 
develop diagnostic and treating strategies for peri-implantitis, effort has been made to 
determine the levels of several proteins associated with bone resorption in the implant 
crevicular fluid from patients with failing dental implants. These proteins include PGE2 , 
soluble RANKL, cathepsin K, and OPG [77-80]. Theses data implicate an important role of 
osteoclasts in the bone loss during peri-implantitis. Additionally, immunohistochemical 
studies have found that T cells are the most prominent cell in peri-implantitis tissue [81], 
suggesting a role of T cells in the pathogenesis of peri-implantitis. Although the involvement 
of T cells in inflammatory conditions such as rheumatoid arthritis has been established [75], 
little is known how T cells contribute to peri-implantitis. It appears that excessive bone loss 
caused by the imbalance of RANKL/RANK/OPG axis plays an important role in 
peri-implantitis; however, more research is needed to better understand the mechanism of 
osteoclast activation and bone resorption in peri-implantitis 
 
2.6. Osteoclasts in Orthodontic Tooth Movement 
  Orthodontic treatment induces bone resorption on the pressure side of a tooth and 
bone formation on the tension side. Interestingly, ankylosed teeth, which lack periodontal 
ligament (PDL), cannot be moved by orthodontic treatment. PDL cells are considered to play 
a pivotal role during orthodontic tooth movement [82]. Indeed, it has been shown that PDL 
cells express both RANKL and OPG, and can support osteoclastogenesis in vitro [82]. Under 
mechanical stress, PDL cells can produce larger amount of RANKL [83, 84]. In addition, 
during orthodontic tooth movement, RANKL level in gingival crevicular fluid is increased, 
while OPG level is decreased [85, 86]. Consistently, local OPG gene transfer to periodontal 
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tissue can decrease orthodontic tooth movement [87], while local RANKL gene transfer to 
the periodontal tissue can increase orthodontic tooth movement [88]. Meanwhile, local 
administration of OPG can inhibit orthodontic tooth movement [89]. Collectively, these data 
indicate the pivotal role of OPG/RANKL/RANK regulatory axis in PDL cells during 
orthodontic tooth movement.  
  Attempts have also been made to address the mechanism underlying the increased 
production of RANKL by PDL cells in response to orthodontic force. Intriguingly, a report 
has suggested that mechanical stress can induce cyclo-oxygenase 2 (COX-2) mRNA 
expression and PGE2 synthesis in PDL cells, which stimulate RANKL expression via an 
atuocrine mechanism [90]. This piece of evidence is in line with the hypothesis that hypoxia 
at the pressure side of PDL plays an important role in inducing bone resorption [91]. Early 
studies have shown that during tooth movement, orthodontic trauma can cause vascular 
changes and hypoxia on the pressure side of PDL, leading to increased production of PGE2 
[91]. In vitro studies have further indicated hypoxia as an important stimulator of osteoclast 
formation and bone resorption [92-94]. Moreover, recent studies have shown that under 
hypoxia conditions, PDL cells can produce larger amount of osteoclastogenic cytokines, 
including IL-6, IL-1β, TNFα, and PGE2 [95]. This is consistent with in vivo findings that 
these cytokines are elevated in gingival crevicular fluid during orthodontic tooth movement 
(reviewed in reference [96]). It is likely that these osteoclastogenic cytokines further 
contribute to the increased osteoclastogenesis by acting on the OPG/RANKL/RANK 
regulatory axis. The important role of TNFα in orthodontic tooth movement is further 
confirmed by genetics studies. Mice lacking the two receptors of both of these receptors 
TNFα (TNFR1 and TNFR1) showed reduced orthodontic tooth movement [97].  
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   Therefore, hypoxia at the pressure side of a tooth undergoing orthodontic tooth 
movement leads to bone resorption by directly or indirectly disrupting the balance of the 
OPG/RANKL/RANK axis in PDL.    
 
2.7. Chapter Summary  
  Osteoclasts are large multinucleated cells present only in bone. They are derived 
from hematopoietic cells. Their formation is a complex and multi-step process, in which 
osteoblasts/stromal cells play a central role by providing two essential factors: M-CSF and 
RANKL. M-CSF induces the proliferation and survival of osteoclast precursors from their 
hematopoietic progenitors, while RANKL stimulates these precursor cells to commit to the 
osteoclast phenotype. Interestingly, osteoblasts/stromal cells can produce an inhibitory factor 
for osteoclastogenesis, OPG, which competes with RANK for RANKL binding. Hormones 
and local factors can exert their effects on bone resorption by regulating OPG and RANKL 
expression in osteoblasts/stromal cells; therefore, the OPG/RANKL/RANK axis represents a 
major means for regulating osteoblast to osteoclast activity and maintaining the balance 
between bone formation and resorption. Osteoclast differentiation also plays an important 
role in periprosthetic osteolysis, peri-implantitis, and orthodontic tooth movement.  
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Figure 2.1. Osteoclastogenesis. Osteoclastogenesis is a multi-step process regulated by a 
sequential series of molecular event. Transcriptional factor PU.1 is critical for the 
determination of hematopoietic stem cells (HSCs) to the myeloid lineage (CFU-GEMM), 
and can also upreguate the expression of M-CSF receptor, c-fms. The binding of M-CSF to 
c-fms ensures the proliferation and survival of monocyte/macrophage lineage precursors 
(CFU-M) from CFU-GEMM. In addition, M-CSF can increase the expression of RANKL 
receptor, RANK. RANKL and RANK binding initiates signaling pathways required for 
CFU-M to assume the osteoclast phenotype.   
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Figure 2.2. M-CSF/RANKL signaling pathways. M-CSF, which is released from 
osteoblasts/stromal cells, binds to its receptor on osteoclast precursors, c-fms. This leads to 
the activation of AKT and ERK pathways through PI3K and GRB2, respectively. These 
signals ensure the survival and proliferation of osteoclast precursors. RANKL on 
osteoblasts/stromal cells recognizes its receptor on osteoclast precursors, RANK, which 
then recruits TRAF6. As a result, NF-κB, Akt, and MAPKs pathways are activated. 
Additionally, RANKL induces the expression of c-Fos, which then activates AP1. The 
common target gene of both NF-κB and AP-1 is NFATc1, whose induction activates the 
expression of osteoclast specific genes. Adapted from references 32 and 33. 
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Figure 2.3. Cooperation of RANKL and ITAM induced signals in osteoclastogenesis. 
Osteoblasts/stromal cells secrete M-CSF, which binds to its receptor on osteoclast precursor 
cells to ensure proliferation and survival of osteoclast precursor cells. Osteoblasts/stromal 
cells also express RANKL, which recognizes RANK on osteoclast precursor cells. RANK 
then binds to TRAF 6, which, in turn, activates NFATc1 through NFκB and c-Fos. In 
addition, transmembrane adapter proteins, FcRγ and DAP12, associate with 
immunoglobulin-like receptors, OSCAR, PIR-A, TREM-2 and SIRPβ1. RANKL/RANK 
signaling (red arrow) and stimulation of the immunoglobulin-like receptors possibly by 
endogenous signals from osteoblastic cells or osteoclastic cells (red arrow with question 
mark) collaboratively phosphorylate ITAM motifs present in those adaptor proteins, and 
then recruit the Syk family kinase to the phosphorylated tyrosine residues. Finally, through 
phospholipase Cγ (PLCγ), the calcium signaling pathway is activated, leading to NFATc1 
induction. Adapted from reference 33.
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Figure 2.4. RANKL-dependent regulation of osteoclast formation. M-CSF secreted by 
osteoblasts/stromal cells can drive myeloid progenitors towards osteoclast precursors. 
RANKL on osteoblasts/stromal cells binds to its receptor RANK on osteoclast precursors 
and thus initiate a signal transduction cascade, leading to osteoclast differentiation. 
Intriguingly, osteoblast/stromal cells also produce a decoy receptor for RANKL, OPG, 
which can block RANK and RANKL binding. This crosstalk mechanism is also an endpoint 
for the actions of several hormones and cytokines, such as estrogen, interleukins, 
prostaglandin E2 (PGE2), TGF-β and parathyroid hormone (PTH). Adapted from reference 
25. 
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CHAPTER III. OSTEOCLAST BIOLGOY: FUNCTION 
 
 
  Osteoclasts have a number of unique ultrastructural characteristics, including 
multiple nuclei surrounded by the full-developed Golgi apparatus, abundant mitochondria, 
and a large number of vacuoles and lysosomes [1]. Functional osteoclasts can be found both 
in trabecular and cortical bone; they are located on the surface of trabeculi in trabecular bone, 
and in the cutting edge of the forming osteons in cortical bone [2].   
 
3.1. Mechanism of Bone Resorption 
  During bone resorption, osteoclasts undergo a transient morphological change [3]. 
Absorbing osteoclasts obtain different membrane domains through cytoskeletal 
reorganization and cellular polarization (Figure 3.1) [2, 3]. The apical membrane domain 
faces the bone surface, and is called the ruffled border. The ruffled border is the main 
resorptive organelle of the cell. Away from the bone surface are the basolateral membrane 
domain and the functional secretory domain. Another important feature of osteoclasts’ zone 
of contact with bone is the sealing zone, an actin-rich area surrounding the ruffled border [3]. 
In the area of the sealing zone, the cell membrane closely interacts with bone matrix via 
integrin αvβ3, thus sealing off an isolated resorptive compartment [1-3]. 
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3.1.1. Dissolving the Mineral Phase 
  The extracellular compartment between the osteoclast and the bone surface is 
acidified by protons transported by the ATP (adenosine triphosphate)-dependent proton 
pumps known as the vacuolar H+- adenosine triphosphatase (H+-ATPase) or V-ATPase at the 
ruffled border. As shown in the reaction below, the low pH value can dissolve the strongly 
basic hydroxyapatite in solid phase, releasing calcium ions, phosphate ions, and water in 
solution [4].  
[Ca3(PO4)2]3 Ca(OH) 2  +  8H+           10Ca2+  +  6HPO42-  +  2H2O 
Solid hydroxyapatite                                    Solution 
Secretion of protons is accompanied by movement of chloride anions via the CLC-7 chloride 
channel at the basolateral membrane [2, 3]. Ion equilibrium in the cytoplasm is maintained by 
the following two processes: 1) the production of protons and bicarbonate ions from CO2 
hydration facilitated by carbonic anhydrase II (CA II); and 2) the exchange of bicarbonate to 
chloride through bicarbonate-chloride (HCO3/Cl) exchanger at the basolateral membrane 
(Figure 3.2.) [2, 3]. Key enzymes involved in the acidification process are very important for 
normal bone resorption. Mutations in H+ATPase, CLC-7 chloride channel or carbonic 
anhydrase II can result in osteopetrosis in mice and humans [3, 5, 6]. 
   
3.1.2. Degrading the Organic Phase 
  While the acidic milieu decalcifies bone, lysosomal enzymes are secreted from the 
ruffled border to degrade the exposed organic matrix in bone [2, 3]. The major enzymes that 
degrade type I collagen in an acid environment include cathepsin K (CTK), a cysteine 
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proteinase, matrix metalloproteinase-9 (MMP-9), and tartrate resistant alkaline phosphatase 
(TRAP) (Figure 3.2.) [2, 7-9]. Genetics studies have demonstrated that mice deficient in 
lysosomal proteases such as TRAP and cathepsin K are osteopetrotic [8, 9].  
 
3.1.3. Removing Resorption Products 
  In order to continue resorption, osteoclasts must have a mechanism to dispose the 
resorption products simultaneously with the ongoing secretion of acid and proteolytic 
enzymes [2]. Studies have demonstrated that degradation products are endocytosed into the 
cell from the ruffled border, transcytosed through the cell, and finally secreted into the 
extracellular fluid through a specific plasma membrane domain. This domain is located in the 
upper part of a resorbing and is called “functional secretory domain” (Figure 3.1.) [2]. It 
should be noted that the process of transcytosis in osteoclasts is not just a disposal process. It 
mobilizes the calcium stored in bone, and it releases growth factors such as transforming 
growth factor-beta (TGF-β ) latent in bone matrix [4].  
 
3.2. Role of Osteoclasts in Hematopoiesis  
  Besides their anatomical juxtaposition, bone and bone marrow are functionally 
associated. On one hand, bone marrow cells provide progenitors of bone remodeling cells 
and regulate their development [10, 11]. On the other hand, osteoblasts have been shown to 
play a central role in supporting hematopoiesis in bone marrow [11, 12]. Intriguingly, recent 
data have demonstrated that the bone-resorbing osteoclasts are critically involved in the 
mobilization of hematopoietic stem cells induced by stress situations such as 
 40
lipopolysaccharide (LPS) administration and controlled bleeding [13]. Stimulation of 
osteoclasts by RANKL, bleeding, or LPS results in elevated production of proteolytic 
enzymes, MMP-9 and CTK, which, in turn, degrade the hematopoietic stem cell niche 
components, including stromal cell-derived factor-1(SDF-1), stem cell factor (SCF), and 
osteopontin [13]. This leads to increased mobilization of HSCs into the circulation. In 
summary, these data associate osteoclasts with the regulation of hematopoiesis and host 
defense, further emphasizing the function interdependence between bone and bone marrow/ 
hematopoiesis (Figure 3.3.).  
     
3.3. Beyond Bone Resorption: Stimulating Bone Formation  
  Osteoclast activity has been traditionally considered as limited to bone resorption; 
however, accumulating evidence has suggested an alternative function of osteoclast: 
stimulating bone formation [14-16]. 
  The very nature of the bone remodeling process, i.e., the coupling between bone 
resorption and bone formation, has long been noticed. It has been hypothesized that the 
coupling mechanism is achieved by growth factors released from bone matrix during 
osteoclastic resorption [14, 15]. However, increasingly more studies have revealed a far more 
complex coupling mechanism: osteoclasts themselves, not their resorptive activity, can 
provide the anabolic signals that can couple bone resorption and bone formation [14, 16]. 
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3.3.1. Evidence from the Osteopetrosis Models  
  In osteopetrosis, bone mass is increased due to reduced bone resorption; however, 
depending on the etiology, bone formation and resorption is not always coupled. Patients 
with mutations in the chloride channel CLC-7 or the H+-ATPase display reduced bone 
resorption due to impaired acidification of the resorption lacunae. However, rather than 
decreased bone formation as expected from the decreased bone resorption, these patients 
exhibit normal or even increased bone formation. Moreover, they have increased number of 
non-resorbing osteoclasts that are otherwise normal [16]. This observation has also been 
confirmed by a recent finding that bone formation is increased in mice with deficiency in 
osteoclast fusion [17]. In contrast to patients with defective acidification process, 
osteopetrosis patients with defective cathepsin K have no apparent uncoupling of formation 
and resorption, but they have poorly remodeled bone. [16].  
  In comparison to osteoclast-rich osteopetrosis mentioned above are osteopetrotic 
models where the osteoclasts are reduced or absent (osteoclast-poor). Studies from op/op 
mice have shown that in the complete absence of osteoclasts, bone formation is impaired, 
with disorganized matrix, reduced mineralization, and a lower bone quality [16, 18]. 
Consistently, c-fos deficient mice, which lack osteoclasts, have markedly decreased serum 
osteocalcin level, suggesting reduced bone formation [16, 19, 20]. 
  Collectively, these data suggest a role of osteoclasts, even those that are not capable 
of resorbing bone, in coupling bone resorption to bone formation.  
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3.3.2. Evidence from the Anabolic Action of PTH  
  Parathyroid hormone (PTH) is a polypeptide hormone secreted by the chief cells of 
the parathyroid glands [21, 22]. PTH has a dual action on bone remodeling. Sustained 
elevations of PTH, as in hyperparathyroidism, have a net catabolic effect on bone, favoring 
bone resorption [21]. The catabolic action of PTH on bone will be discussed in detail in 
Chapter V. Interestingly, when administered in an intermittent, rather than a continuous 
mode, PTH has an anabolic action on bone [21]. 
  This has raised the question whether the resorptive action of PTH is necessary for its 
anabolic action on bone formation. As indicated by both human and animal studies, the 
anabolic effect of PTH is not solely dependent on osteoblasts; it also requires signals from 
osteoclasts linking back to osteoblasts [14, 23]. 
  The anabolic effect of PTH is significantly reduced when the subjects are 
co-administered with agents that promote osteoclast apoptosis, such as bisphosphonate or 
estrogen [14]. Mice deficient with c-fos are osteopetrotic and lack the anabolic response to 
intermittent PTH treatment [14, 23]. Compared to those from normal mice, osteoblasts from 
c-fos knockout mice showed no different response to PTH treatment in vitro. In contrast, the 
rescue of osteoclast defect in c-fos mutant mice can restore the anabolic effect of PTH, 
suggesting osteoclasts are required for the anabolic response to PTH. Moreover, in normal 
mice, the anabolic action of PTH is significantly blocked when osteoclast precursors 
recruitment is inhibited by stromal derived factor-1 (SDF-1) or osteoclast differentiation is 
inhibited by OPG [23]. Taken together, these data demonstrate that the osteoclast is the 
intermediate target for the anabolic action of PTH [23].  
 43
  In addition, the underlying mechanism has been further proposed: PTH can increase 
production of RANKL, which stimulate the transient activation of osteoclasts. 
RANKL-activated osteoclasts then provide signals for osteoblast maturation (Figure 3.4.) 
[14]. 
  In summary, studies from the anabolic action of PTH further emphasize the 
important role of osteoclasts in providing signals required in coupling bone resorption to 
bone formation during bone remodeling.  
 
3.3.3. Evidence from In Vitro Studies 
  In order to identify the anabolic factor(s) produced by osteoclasts, a recent study 
employed an in vitro cell culture system, where primary human osteoclasts were induced by 
recombinant RANKL and M-CSF. The results showed that even conditioned media collected 
from osteoclasts cultured on plastic can promote bone nodule formation by the murine 
osteoblastic cell line, MC3T3-E1, in a dose dependent manner [24]. Although the authors 
claimed that this was the first evidence that osteoclasts can secrete non-bone matrix derived 
factor(s) to increase bone formation, this is not exactly the case. In fact, studies have been 
performed to address the question whether osteoclasts control osteoblastic growth and 
function. Factors expressed by osteoclasts have been found to be able to regulate osteoblast 
differentiation and proliferation: hepatocyte growth factor (HGF) and myeloid protein-1 
precursor (Mim-1) as positive regulators, while platelet-derived growth factor BB (PDGF) as 
negative regulators [25]. Nevertheless, these preliminary data still remain controversial and 
more research is required to identify the factor(s) secreted by osteoclasts that can regulate 
osteoblasts.  
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3.4. Chapter Summary  
  Osteoclasts are the sole bone-absorbing cells. They decalcify bone by producing 
acid and degrade bone matrix by secreting lysosomal proteases. By resorbing bone, 
osteoclasts also play a critical role in mobilizing hematopoietic stem cells in response to 
stress situations, such as LPS treatment. Moreover, accumulating data have indicated that 
osteoclast activity is not limited to bone resorption. Osteoclasts can stimulate bone formation, 
serving as a source of anabolic signals to couple bone formation to bone resorption. The 
underlying molecular mechanism, however, still remains to be defined.  
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Figure 3.1. Plasma membrane domains present in a resorbing osteoclast. Adapted from 
reference 2.  
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Figure 3.2. Mechanism of osteoclastic bone resorption. The osteoclast adheres to bone 
surface via integrin αvβ3, and forms a special membrane facing bone: the ruffled border. 
Hydrochloric acid is secreted into the resorptive lacuna by the combined actions of a 
vacuolar H+ ATPase, its coupled Cl– channel, and a basolateral chloride–bicarbonate 
exchanger. Carbonic anhydrase II (CA II) converts CO2 and H2O into H+ and HCO3–. The 
acidic milieu mobilizes the mineral phase of bone and thereby exposing the organic phase 
of bone for degradation by acidic proteases released from lysosomes, such as cathepsin K 
(CTK). Adapted from reference 2.  
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Figure 3.3. Osteoclasts mobilize hematopoietic stem cells into circulation. Stimulation 
of osteoclasts by RANKL or stress situations such as inflammation and injury results in 
elevated production of proteolytic enzymes, MMP-9 and CTK, which, in turn, degrade 
components of the hematopoietic stem cell niche. This leads to increased mobilization of 
the hematopoietic stem cells from bone marrow into the circulation. Adapted from 
reference 13.  
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Figure 3.4. Mechanism of the anabolic action of PTH. An anabolic stimulus, PTH, 
increase transiently RANKL production by osteoblasts, which results in the activation of 
osteoclasts. Osteoclasts then send coupling signals to stimulate osteoblast differentiation 
and bone formation. Adapted from reference 14. 
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CHAPTER IV. OSTEOCLAST PATHOLOGY: BONE LOSS 
    
  
  Bone resorption plays an important role not only in bone development and 
physiology, but also in bone pathology. The discovery of the OPG/RANKL/RANK axis as a 
major regulatory mechanism of osteoclastogenesis has revolutionized our understanding of 
normal bone biology and a number of bone diseases as well [1-3].  
 
4.1. Postmenopausal Osteoporosis 
4.1.1. Introduction 
  Osteoporosis is a heterogeneous group of metabolic bone diseases [4] and has been 
defined as “a skeletal disorder characterized by compromised bone strength predisposing a 
person to an increased risk of fracture” [5]. Although osteoporosis is characterized by low 
bone mass, the ratio of bone mineral to the organic matrix in osteoporosis normal, as opposed 
to a decreased ratio of bone mineral to the organic matrix in osteomalacia [6, 7].  
  In clinical practice, the measurement of bone mineral density (BMD) is the most 
commonly used method for osteoporosis diagnosis. BMD is most often assessed by dual 
energy x-ray absorptiometry (DXA or DEXA) [5, 8]. DXA measures both bone mineral 
content (BMC, in grams) and area (in cm2). An “areal” BMD (g/cm2) is obtained by dividing 
bone mineral content by area. This value can be converted to a T score or a Z score. A T score 
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compares a patient to a sex-matched, young, healthy population; it is calculated by 
subtracting the mean BMD of a young adult healthy population from the patient’s BMD and 
then dividing by the standard deviation (SD) of the reference population. A Z score compares 
a patient to an age-and sex-matched control population; it is calculated by subtracting the 
mean BMD of an age- and sex-matched control population from the patient’s BMD and then 
dividing by the SD of the reference population [9]. T scores are often reported in 
postmenopausal women and men of 50 years age and older, while Z scores are often reported 
in premenopausal women, men under the age of 50, and children [9]. According to the WHO 
definition, the diagnosis of osteoporosis is established when BMD is 2.5 SDs below the mean 
for normal Caucasian women (i.e. the T score is at least −2.5 SDs) [5].  
  However, it has been argued that the measurement of bone mass does not account 
for another important determinant of bone strength—bone quality [10, 11]. Bone quality is 
independently influenced by parameters including bone architecture, bone turnover, 
microdamage, and mineralization [5]. Although BMD measurement is currently the best 
diagnostic practice, alternative methods that can detect the deterioration in bone quality will 
provide significant improvement in osteoporosis prevention, diagnosis, and treatment [11]. 
  Osteoporosis can occur as a primary disorder or as a disorder secondary to a number 
of systemic diseases (e.g. hyperparathyroidism) or medications (e.g. glucocorticoids) [6]. 
Primary osteoporosis is the most common metabolic bone disorder in adults, mostly 
associated with aging. There are two clinical subtypes of age-related osteoporosis: 1) Type I 
or postmenopausal osteoporosis, which occurs in postmenopausal women; and 2) Type II or 
senile osteoporosis, which is associated with the normal aging process in both men and 
women [4, 12]. Menopause refers to the cessation of menstruation, which occurs at ~ 48-50 
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years of age for healthy women. As a result, the production of ovarian hormones including 
estrogen is reduced [6]. The pathogenesis of postmenopausal osteoporosis will be discussed 
below with a focus on the current understanding of estrogen action on osteoclastic bone 
resorption.  
   
4.1.2. Cellular Pathogenesis  
  Under normal conditions, bone undergoes constant remodeling, where resorption of 
the existing bone by osteoclasts is tightly coupled to formation of new bone by osteoblasts 
[13]. In postmenopausal osteoporosis, the rate of bone remodeling is increased, i.e. increased 
number of osteoclasts and bone resorption coupled with increased number of osteoblasts and 
bone formation. However, due to estrogen deficiency, there is an imbalance between bone 
resorption and bone formation, resulting in a decrease in total bone mass [4, 7].    
 
4.1.3. Indirect Effects of Estrogen Deficiency on Bone Resorption 
  Since the interplay between the immune system and bone has long been noticed 
[14], it is no surprise that the pathogenesis of bone loss in postmenopausal osteoporosis is 
mainly mediated by immune cells [15, 16]. Indeed, many studies have suggested that 
stimulation of bone resorption in response to estrogen deficiency is largely mediated by 
inflammatory and osteoclastogenic cytokines, such as IL-1, IL-6, TNFα, and IL-7 [7, 15, 17, 
18]. These cytokines are able to increase the production of M-CSF by osteoblasts/stromal 
cells and/or the ratio of RANKL to OPG, thereby upregulating osteoclastogenesis [7, 18].  
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  Among these cytokines, TNFα  and IL-7 have been shown to be the major ones. The 
source of TNFα  in postmenopausal osteoporosis has been identified to be T cells [16]. 
TNFα  can stimulate osteoclastogenesis by enhancing osteoblasts/stromal cells to produce 
more RANKL and M-CSF, and by priming osteoclast precursors to the stimulation of 
RANKL. Meanwhile, TNFα  can inhibit osteoblast differentiation by repressing 
transcription factor, Runx2 [15]. A lack of estrogen results in elevated levels of circulating 
cytokines, such as IL-1 and TNFα, which, in turn, stimulate osteoblasts/stromal cells to 
release more IL-7 [17]. On one hand, IL-7 decreases Runx2 activity, and hence inhibits 
osteoblast function [17, 19]. On the other hand, IL-7 stimulates the expression of M-CSF and 
RANKL and simultaneously decreases OPG expression by osteoblasts/stromal cells. 
Moreover, IL-7 targets T cells to induce RANKL production [15, 17].  
   In summary, TNFα  and IL-7 are the key mediators involved in bone lose induced 
by estrogen withdrawal.  
 
4.1.4. Direct Effects of Estrogen Deficiency on Bone Resorption 
  The physiological effects of estrogen are mediated by two nuclear hormone 
receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with the former 
being the major one in most target tissues [7, 18]. Estrogen receptors are also expressed in 
bone cells, including bone-absorbing osteoclasts and their precursors [7, 18], which indicates 
that the effects of estrogen on bone resorption may be mediated, at least in part, directly. 
However, until recently little is known regarding the direct action of estrogen on osteoclasts 
[18].  
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  Using an osteoporosis mouse model, a recent publication has elegantly 
demonstrated that estrogen can directly induce osteoclast apoptosis [20]. To specifically 
disrupt ERα gene in mature osteoclasts, the authors inserted the Cre recombinase into the 
cathepsin K gene locus. In another word, ERα  gene is selectively deleted during 
osteoclastogenesis. Adult female, but not male, ERΔOc/ΔOc mice displayed high bone turnover 
characterized by increased osteoclast numbers, increased bone formation, but decreased 
trabecular bone mass [20]. So these mice mimic, to a certain degree, human postmenopausal 
osteoporosis. However, in ERΔOc/ΔOc mice, ovariectomy did not result in trabecular bone loss 
or increased osteoclast numbers. In addition, estrogen administration could not rescue the 
osteoporotic phenotypes of these mice. These results suggest that estrogen may directly 
target osteoclasts to exert its osteoprotective action.  
  This report further demonstrated that estrogen can upregulate Fas ligand (FasL) 
expression in osteoclasts and thus induce apoptosis of osteoclasts having wildtype ERα , but 
not those lacking ERα [20]. Since Fas is also expressed by osteoclasts, it appears that 
estrogen can upregulate FasL expression and affect osteoclast survival through an autocrine 
mechanism [21]. Collectively, these data suggested that estrogen can directly induce 
osteoclast apoptosis via its receptor ERα in osteoclasts [21]. In contrast, a more recent article 
has described a paracrine mechanism in which estrogen control osteoclast life span by 
upregulating FasL in osteoblasts, not osteoclasts [22]. Therefore, to generate a complete 
picture of the extremely complex process of postmenopausal osteoporosis, more research is 
necessary to identify the central cellular target(s) of estrogen.  
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 4.2. Paget’s Disease of Bone   
  Paget’s disease of bone (PDB), also known as osteitis deformans, is a nonmalignant, 
localized, metabolic bone disorder [23]. It is characterized by enlarged and deformed bone, 
occurring mainly in the axial skeleton [23].   
   
4.2.1. Cellular Pathogenesis  
  Histological studies have shown that the primary cellular abnormality in Paget’s 
disease of bone is the increased activity of osteoclasts [6, 23]. Compared to normal 
osteoclasts, Pagetic osteoclasts are larger and contain more nuclei, causing excessive bone 
resorption. Subsequently, more osteoblasts are recruited to the site, and bone formation is 
increased. However, new bone is formed at such a rapid rate that bone is formed in a sporadic 
and haphazard way, and woven bone rather than lamellar bone develop. Pagetic bone is 
expanded in size, structurally disorganized, and mechanically weak, leading to bone 
deformity, pathological fracture, and various other complications [23, 24]. In Paget’s disease 
of bone, increased osteoclastic bone resorption coupled to increased bone formation leads to 
accelerated and abnormal bone remodeling.  
 
4.2.2. Molecular Pathogenesis  
  Paget’s disease of bone is the second most common bone disease after osteoporosis, 
but its etiology remains largely unknown [23]. Two main theories have been proposed: viral 
and genetic. Infection of virus, such as the measles virus, the canine distemper virus, and the 
respiratory syncytial virus, may contribute to the osteoclast hyperactivity in genetically 
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susceptible individuals [23]. Although the virus theory is still controversial, genetic factors 
are certainly involved in Paget’s disease of bone. This disorder shows autodominant 
inheritance, and is called familial Paget’s disease. Ethnic difference in the prevalence also 
suggests the importance of genetic factors [25]. Several rare familial bone conditions have 
been described to share clinical features phenotypes with Paget’s disease of bone (classical 
PDB) [25]. These diseases are summarized in Table 4.1.  
  Several susceptibility loci for Paget’s disease of bone and related syndromes have 
been identified by genome-wide scans. Mutations that predispose individuals to PDB and 
related disorders have been subsequently identified in four genes, all of which are involved in 
one of the pathways essential for osteoclastogenesis — the RANKL–RANK–NFκB signaling 
pathway [25].  
  As discussed in Chapter II, the binding of RANKL produced by osteoblasts/stromal 
cells to its receptor, RANK on osteoclasts and their precursors initiates signaling pathways 
(e.g. NFκB pathway) to induce osteoclast differentiation (Figure 2.2.)[26-28]. Meanwhile, 
osteoblasts/stromal cells also produce a decoy receptor to RANKL— OPG— to negatively 
regulate RANKL induced signals (Figure 2.2.) [3, 29, 30]. The familial expansile osteolysis, 
early-onset PDB, and ESH are caused by insertion mutations in TNFRSF11A, which encodes 
RANK. Inactivating mutations in TNFRSF11B, which encodes osteoprotegerin (OPG) cause 
JPD, and polymorphisms in this gene are associated with an increased risk for PDB (Figure 
4.1.) [25]. 
  The most important cause of classical PDB is the mutations of SQSTM1 gene, which 
encodes ubiquitin-binding protein p62 (sequestosome 1) [31]. The ubiquitin-binding protein 
p62 (SQSTM1) functions as a scaffold in a range of signaling pathways including the NFκB 
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pathway [32, 33]. Studies have suggested that RANKL stimulation leads to the formation of a 
complex involving TRAF6, p62, and atypical protein kinase C (aPKC), the latter activating 
IKK (IκB kinase) and NF-kB (Figure 4.1.) [32, 34].  
  IBMPFD is caused by mutations in the gene encoding valosin-containing protein 
(VCP) [25]. VCP is a protein involved in targeting the inhibitor of NFκB (IκB) for 
proteasomal degradation. The degradation of IκB results in the release of NFκB, which then 
translocates to the nucleus to activate responsive genes. Together with other signaling 
pathways described in Chapter II, NFκB signaling eventually leads to osteoclast 
differentiation (Figure 4.3.) [35].  
  In summary, mutations or polymorphisms in genes implicated in PDB and related 
disorders are all involved in the osteoclastogenesis signaling pathway, 
RANKL–RANK–NFκB pathway.  
 
4.3. Hyperparathyroidism 
  Primary hyperparathyroidism is a hypercalcemia state resulting from excessive 
secretion of parathyroid hormone (PTH) by parathyroid glands [36].This can be caused by 
adenoma, hyperplasia, or carcinoma of the parathyroid glands [6]. Secondary 
hyperparathyroidism is an acquired disorder in which parathyroid glands secrete excessive 
PTH in response to a low extracellular calcium concentration [6].  
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4.3.1. Cellular and Molecular Pathogenesis  
  PTH is a polypeptide hormone secreted by the chief cells of the parathyroid. PTH 
has a dual action on bone remodeling. When administered in an intermittent, rather than a 
continuous mode, PTH has an anabolic action on bone [37]; the underlying mechanism has 
been discussed in detail in Chapter III. As discussed in the following sections, sustained 
elevations of PTH have a net catabolic effect on bone [37]. 
  Small fluctuations in plasma Ca2+ level is sensed by a cell surface Ca2+ receptor 
(CaR) on parathyroid gland cells. CaR belongs to the superfamily of G protein-coupled 
receptors (GPCR) [38]. Under hypocalcemic conditions, the parathyroid CaR senses the 
decreased Ca2+ level and enhances PTH secretion. PTH can mobilize Ca2+ into the 
extracellular fluid through the following mechanisms: 1) stimulation of bone resorption; 2) 
increasing renal calcium reabsorption; and 3) stimulation of renal 1α, 25-dihydroxyvitamin 
D3 [1,25(OH)2D3 ] (Figure 4.2.) [38]. Under hypercalcemic conditions, the parathyroid CaR 
senses the elevated Ca2+ level and inhibits PTH secretion, leading to suppressed calcium 
mobilization (Figure 4.2.) [38].  
  Such a feedback mechanism is disrupted in both primary hyperparathyroidism and 
secondary hyperparathyroidism. In primary hyperparathyroidism, the pathology of 
parathyroid glands themselves causes sustained elevation of plasma PTH level, which, in turn 
causes excessive bone resorption and diminished bone mineral density [36, 38, 39]. Primary 
hyperparathyroidism is the most common cause of hypercalcemia [6]. In secondary 
hyperparathyroidism, in response to a low extracellular calcium concentration, parathyroid 
glands synthesize more PTH to restore the normal plasma calcium level. However, due to a 
disorder within organs responsible for calcium or reduced availability of calcium, 
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hypocalcemia can occur. Secondary hyperparathyroidism is the most common complication 
of end stage renal diseases, and is also found in vitamin D-deficiency and Vitamin-D- 
resistant conditions [6].  
 
4.3.2. Mechanism of PTH Catabolic Effect on Bone 
  The physiological activities of PTH are mediated by its receptor, PTH1R, a G 
protein-coupled protein (GPCR) [40]. As in primary hyperparathyroidism, continuous 
increase of PTH level leads to the activation of PTH1R expressed on the plasma membrane of 
osteoblasts. The binding of PTH and its receptor initiates downstream signaling to stimulate 
RANKL expression and inhibit OPG expression by osteoblasts. The increased RANKL to 
OPG ratio results in increased osteoclastogenesis [1, 2, 41]. The responsible signal 
transduction pathway is the classic cAMP-dependent protein kinase A (PKA) pathway, in 
which Gαs subunit of PTH1R stimulates cAMP production and PKA activation; PKA 
subsequently phosphorylates transcription factors, such as Cbfa1 and cAMP-response 
element-binding protein (CREB), regulating target gene expression [2, 42]. Additionally, 
recent studies have demonstrated that PTH can increase osteoblastic production of monocyte 
chemoattractant protein-1(MCP-1), which, in turn, increases osteoclastogenesis [43]. 
  Osteoblasts have been widely shown to express PTH receptors [1, 44], while it has 
been controversial whether osteoclasts express high-affinity PTH receptors [45-47]. It is 
generally accepted that even though osteoclast may express PTH receptors, these receptors 
do not respond directly to PTH; the functional significance of the osteoclastic PTH receptors, 
if any, need to be further confirmed and elucidated [46, 47]. Therefore, PTH exerts its 
catabolic action on bone indirectly via its action on osteoblasts [1, 44].  
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4.4. Cherubism 
  Cherubism (OMIM reference number #118400) is an autosomal-dominant benign 
disorder characterized by painless symmetrical swelling of cheeks and jaws [48-50]. Dental 
abnormalities such as hypodontia are also a feature [49, 51]. With an early onset at ~2-4 years 
of age, this condition continues through childhood before regressing in adulthood [52]. 
Histologically, cherubism is characterized by fibrous connective tissue with abundant 
osteoclastic cells and inflammation cells [52]. 
 
4.4.1. Molecular Pathogenesis 
  The cherubism locus has been mapped to chromosome 4p [53, 54], and genetic 
studies have subsequently detected several point mutations in SH3BP2, which encodes the 
widely expressed scaffold protein, the SH3-domain binding protein 2 (SH3BP2) [48]. 
However, the exact pathogenesis of this disease is largely unclear.  
  A recent publication has shed new light on this condition by using a mouse model of 
cherubism. This mouse model is created by introducing the most common SH3BP2 mutation 
found in cherubism patients, P418R (a proline to arginine substitution affecting amino acid 
418), into the mouse SH3BP2 gene (P416R) [55]. Mice homozygous for this mutation 
exhibited bone resorption in the jaws associated with increased osteoclast numbers, a global 
decrease in bone mass, and systemic macrophage-infiltrated inflammation [55].  
  The following two major findings were generated from this knockin mouse model. 
First, several pieces of evidence have suggested that the primary cell type involved in 
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cherubism pathogenesis is the myeloid cell: 1) Myeloid osteoclast precursors from SH3BP2 
knockin mice showed increased osteoclastic potential in culture in response to macrophage 
colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand 
(RANKL); 2) The phenotypes can be transferred into wildtype mouse by transplantation of 
fetal liver cells from SH3BP2 knockin mice; 3) When SH3BP2 knockin mice were crossed 
with rag1−/−mice, which lack functional lymphocytes, the phenotypes were not changed; 
however, when SH3BP2 knockin mice were crossed with op/op mice, which lack myeloid 
cells, the phenotypes were eliminated [55]. Secondly, the pathogenesis of cherubism is 
dependent on TNFα [55], a potent stimulator of osteoclastogenesis [56]. SH3BP2 knockin 
mice had elevated level of serum TNFα, and myeloid cells isolated from the knockin mice 
produced an increased amount of TNF-α in response to M-CSF treatment in an ERK 
dependent manner. Moreover, when SH3BP2 knockin mice were crossed with 
TNFα-deficient mice, they did not exhibit bone loss or inflammation [55].  
  The authors have further demonstrated that P416R mutation of SH3BP2 in the 
osteoclast lineage cells causes gain of function, leading to hyperphosphorylation of Syk and 
increased Syk activity in response to RANKL [55]. Syk is a tyrosine kinase involved in the 
costimulatory signals for RANK in osteoclastogenesis (see Figure 2.3. for detail) [57]. Since 
SH3BP2 can mediate ITAM-dependent activation of calcium signaling and NFATc1 
induction in lymphocytes, it has been proposed that it may also act as an ITAM-dependent 
scaffold protein in osteoclast precursors [58]. Based on their findings, the authors have 
proposed a mechanism of Cherubism pathogenesis shown in Figure 4.3. 
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4.5. Chapter Summary  
  Despite of distinct etiologies, metabolic bone diseases, such as osteoporosis, Paget’s 
disease of bone, and hyperparathyroidism are all characterized by excessive osteoclast 
activities and bone loss [2]. Estrogen deficiency leads to increased levels of osteoclastogenic 
cytokines produced by immune cells, which stimulate osteoclastogenesis through the 
RANKL/RANK/OPG system. Moreover, recent research has shown that estrogen can also 
directly target osteoclasts, inhibiting their apoptosis. Increased osteoclastogenesis in Paget’s 
disease of bone and related syndromes is caused by mutations in genes involved in the 
RANKL–RANK–NFκB signaling pathway. In hyperparathyroidism, sustained increased of 
PTH levels results in increased bone resorption to mobilize calcium from bone. PTH binds to 
its receptor, PTH1R on osteoblasts, leading to increased production of RANKL and 
decreased production of OPG.  In addition, excessive bone resorption in the jaws is also an 
important characteristic of Cherubism, an autosomal-dominant disorder. [48]. Animal studies 
have recently shown that mutation in SH3BP2 gene, which encode a scaffold protein, results 
in increased responsiveness of osteoclast precursors to M-CSF/RANKL and increased 
production of TNFα by macrophages. TNFα further stimulate osteoclastogenesis by acting 
on osteoblasts/stromal cells. Further investigation is needed to define the extent to which the 
cherubism mouse model can recapitulate what happens in humans with cherubism.  
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Table 1. Familial bone conditions with similar clinical features as Paget’s disease of 
bone (PDB)  
 
Juvenile Paget’s Disease (JPD) 
Familial Expansile Osteolysis (FEO) and Expansile Skeletal Hyperphosphatasia (ESH) 
Early-Onset Paget’s Disease of Bone 
Inclusion-Body Myopathy, PDB and Frontotemporal Dementia (IBMPFD) 
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Figure 4.1. Mutations in components of RANK–NFκB signaling pathway cause Paget’s 
disease of bone and related disorders. The binding of RANKL produced by 
osteoblasts/stromal cells to its receptor, RANK on osteoclasts and their precursors leads to 
the formation of a complex involving TRAF6, ubiquitin-binding protein p62, and aPKC, the 
latter activating IKK (IκB kinase) to phosphorylate IκB. IκB is then targeted for 
proteasomal degradation, a process that involves valosin-containing protein (VCP). The 
degradation of IκB results in the release of NFκB that translocates to the nucleus to activate 
the responsive genes. Together with other signaling pathways described in Chapter II, 
NFκB signaling eventually leads to osteoclast differentiation. Stromal cells/osteoblasts also 
produce a decoy receptor for RANKL, osteoprotegerin (OPG), which negatively regulate 
RANK signaling. Components of the RANK−NFκB pathway that are mutated or 
polymorphic in Paget’s disease of bone and related disorders are highlighted in red: 1) 
RANK mutations can cause the familial expansile osteolysis (FED), ESH and early-onset 
PDB; 2) OPG mutations can cause juvenile PDB, and polymorphisms in this gene increases 
the risk for PDB; 3) Mutations of genes encoding p62 can cause classical PDB; 4) 
Mutations of genes encoding VCP can cause IBMPFD. Adapted from reference 25. 
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Figure 4.2. Reciprocal relationship between PTH and extracellular calcium level. PTH 
secretion is triggered by hypocalcemia, and suppressed by hypercalcemia. Hypocalcemic 
conditions: the parathyroid CaR senses the decreased Ca2+ level and enhances PTH 
secretion. PTH can mobilize Ca2+ into the extracellular fluid through the following 
mechanisms: (1) stimulation of bone resorption; (2) increasing renal calcium reabsorption; 
(3) stimulation of renal 1α, 25-dihydroxyvitamin D3 [1,25(OH)2D3 ]. Consequently, 
hypocalcemia returns to normocalcemia. In contrast, under hypercalcemic conditions, the 
parathyroid CaR senses the elevated Ca2+ level and inhibits PTH secretion, leading to 
suppressed calcium mobilization. Consequently, hypercalcemia returns to normocalcemia. 
Adapted from reference 38. 
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Figure 4.3. Proposed mechanism of cherubism pathogenesis. Mutation in SH3BP2 gene 
results in an increased response of myeloid cells to M-CSF and RANKL. In the presence of 
M-CSF, the cells differentiate into macrophages with increased production of TNFα. When 
exposed to both M-CSF and RANKL, they differentiate into osteoclasts with increased 
bone-resorbing capability. Moreover, TNFα can increase the production of M-CSF and 
RANKL by stromal cells/osteoblasts, further promoting macrophage and osteoclast 
differentiation. Therefore, macrophage/TNFα mediated inflammation and osteoclastic bone 
loss becomes the pathological characteristic of cherubism. Adapted from references 55 and 
58.  
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CHAPTER V. BONE PHARMACOLOGY: TARGETING THE OSTEOCLAST 
 
  
  For diseases associated with excessive bone resorption, osteoclasts are the primary 
therapeutic targets [1]. The bisphosphonate is currently considered a major class of 
antiresorptive drug because of its ability to induce osteoclast apoptosis [2]. Meanwhile, 
stimulators of bone formation can also be a desirable addition to antiresorptive therapy. 
However, clinical application of the most potent anabolic agent available, fluoride, still 
remains controversial [3].  
5.1. Bisphosphonates 
  Bisphosphonates are the primary drugs prescribed for the treatment of osteoporosis 
and other bone diseases associated with excessive bone resorption [2]. Bisphosphonates, 
formerly called diphosphonates, are stable analogues of naturally-occurring inorganic 
pyrophosphate (PPi) [2]. In bisphosphonates, the two phosphate groups are connected by a 
carbon atom, rather than an oxygen atom as in pyrophosphate (Figure 5.1.), which makes the 
compounds resistant to chemical and enzymatic hydrolysis [4]. 
  Like pyrophosphate, bisphosphonates have high binding affinity for bone mineral. 
Exploration of bisphosphonates as potential inhibitors of bone absorption was initiated by its 
property of inhibiting hydroxyapatite dissolution [4]. However, later studies have shown that 
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the anti-resorptive action of these compounds is mediated by cellular mechanisms rather than 
simply physicochemical mechanisms [2]. 
 
5.1.1. Bone Uptake of Bisphosphonates 
  After administration, approximately 1/3~2/3 of bisphosphonates are localized in 
bone, and the remaining are removed by urinary excretion within the first few hours.  
Intestinal absorption of bisphosphonates is very low [4]. Bisphosphonates initially localize to 
bone-forming sites and bone-resorbing sites, where a large amount of exposed mineral is 
available [2]. Much of the bisphosphonates binding to bone are rapidly buried in bone and 
become pharmacologically inactive. These bisphosphonates can be retained for a long period 
of time within bone and can also be released from bone surfaces [2, 4]. Two mechanisms of 
the release of bisphosphonates from bone surfaces have been proposed: 1) chemical 
desorption occurring when bisphosphonate concentration in the extracellular fluid is 
dropped; 2) osteoclastic bone resorption [2].  
 
5.1.2. Cellular Uptake of Bisphosphonates 
  Due to their marked binding affinity for bone rather than other tissues, 
bisphosphonates are in close contact with bone cells [2]. Using fluorescent-labeled 
bisphosphonates, researchers have localized bisphosphonates in intracellular endocytic 
vesicles [5, 6]; acidification of these vesicles appears to be necessary for the movement of 
bisphosphonates from vesicles into the cytosol [6]. Compared to non-resorbing cells such as 
osteoblasts and macrophages, osteoclasts are able to internalize a larger amount of 
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bisphosphonates because of their ability to release these compounds from hydroxyapatite 
during bone resorption [5].  
 
5.1.3. Biochemical Effects of Bisphosphonates on Osteoclasts 
  According to their modes of action, bisphosphonates can be classified into two 
major groups (Figure 5.2.). The first group is the simpler, non–nitrogen-containing 
bisphosphonates, including clodronate and etidronate; while the second group is the more 
potent, nitrogen-containing bisphosphonates, including alendronate, risedronate, and 
zoledronate [4]. 
 
5.1.3.1. Non–nitrogen-containing Bisphosphonates 
  The simple, non–nitrogen-containing bisphosphonate can be incorporated into a 
non-hydrolyzable analogue of adenosine triphosphate (ATP or Appp), AppCp, which 
contains the P-C-P moiety in place of the β, γ-phosphate groups present in ATP [4, 7]. This 
incorporation is brought about by the cyoplasmic enzyme, aminoacyl-tRNA synthetase, 
which plays an essential role in protein synthesis. This enzyme can catalyse a two-step 
reaction to form an aminoacyl-tRNA (Figure 5.3.) [4, 8]. First, in a reversible reaction, an 
amino acid condenses with ATP (Appp) to form an aminoacyl-adenylate (amino acid-AMP), 
releasing pyrophosphate (PPi) (reaction I). The amino acid-AMP then condenses with a 
molecule of tRNA to form aminoacyl-tRNA (reaction II). Since bisphosphonates (pCp) with 
short side chains resemble PPi structure, the reverse reaction of reaction I can occur with pCp 
in place of PPi, forming an analogue of ATP, AppCp [7]. The ATP analogues are 
nonhydrolysable and are accumulated intracellularly in osteoclasts, causing osteoclast 
 75
apoptosis, possibly by the inhibition of intracellular ATP-dependent enzymes [4]. In 
summary, non–nitrogen-containing bisphosphonates can be metabolically incorporated into 
non-hydrolysable analogues of ATP and thereby cause osteoclast apoptosis.  
  
5.1.3.2. Nitrogen-containing Bisphosphonates  
  Nitrogen-containing bisphosphonates induce osteoclast apoptosis predominantly by 
the inhibition of the mevalonate pathway. The mevalonate pathway is an important 
biosynthetic pathway responsible for the production of cholesterol and isoprenoid lipids, 
such as isopentenyl pyrophosphate (IPP), farnesyl pyrophosphate (FPP), and geranylgeranyl 
pyrophosphate (GGPP) (Figure5.4.) [8, 9]. The sequential condensation of isopentenyl 
pyrophosphate (IPP) with dimethylallyl pyrophosphate (DMAP) and geranyl pyrophosphate 
(GPP) is catalyzed by an enzyme named farnesyl pyrophosphate synthase (FPPS) (Figure 
5.4.). Nitrogen-containing bisphosphonates act as substrate analogues for GPP and compete 
with GPP for the binding of FPPS, leading to competitive inhibition of FPPS [4, 7]. 
  FPP and GGPP are substrates for the prenylation (post-translational modification) of 
small GTPases, which are important for osteoclast functions and survival [4, 10]. Therefore, 
by inhibiting FPPS, nitrogen-containing bisphosphonates can block the synthesis of FPP and 
GGPP and subsequent prenylation of small GTPase proteins, leading to osteoclast apoptosis 
[2].  
  In summary, by inhibiting farnesyl pyrophosphate synthase (FPPS) in the 
mevolonate pathway, nitrogen-containing bisphosphonates can inhibit the synthesis of 
isoprenoid compounds, which are substrates for the prenylation of GTPases. This leads to the 
disruption of GTPases functions and eventually the apoptosis of osteoclasts.   
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5.1.4. Biochemical Effects of Bisphosphonates on Osteoblasts and Osteocytes 
  Recent studies have suggested that bisphosphonates can protect osteocytes and 
osteoblasts from apoptosis [2, 11]. Bisphosphonate treatment leads to the opening of a gap 
junction protein present in osteoblasts and osteocytes—connexin 43 hemichannels [11-14]. 
Connexin 43 hemichannel opening results in the activation extracellular signal-regulated 
kinases (ERKs), promoting cell survival [11, 12]. In contrast, induction of osteoblast 
apoptosis by bisphosphonates has also been reported [15]. Moreover, investigation regarding 
the direct action of bisphosphonates on osteoblast differentiation and proliferation has 
yielded mixed results [15-18]. Therefore, to fully understand the effects of bisphosphonate on 
bone, the potential interaction of bisphosphonates with osteoblasts/osteocytes needs to be 
further determined.  
 
5.2. Fluoride                                      
  Fluorine is the 17th most abundant element in the earth's crust [19]. Fluoride can 
be found from a variety of sources and is present in the food chain consumed by humans. 
The normal food chain supports plasma levels in adults ranging from 0.5 to 2.3 μM [19]. 
Fluoride is rapidly and extensively absorbed from the gastrointestinal tract. It is removed 
from plasma by urinary excretion and bone uptake [19, 20].  
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5.2.1. In Vivo Effects on Bone 
  It has long been noticed that fluoride exerts a biphasic action on bone [21, 22]. 
There is a correlation of the severity of skeletal changes and the magnitude and duration of 
fluoride exposure. At low levels of chronic exposure, fluoride can increase bone density 
with little effect on the overall health of bone, while prolonged and heavy exposure results 
in marked skeletal changes, including periosteal bone formation, ligament calcification, and 
joint stiffness [19]. The latter is known as skeletal fluorosis, a bone and joint condition that 
can be categorized into occupational and endemic skeletal fluorosis [23].  
  This dual action of fluoride on bone has led to exploration of the therapeutic 
potential of fluoride in osteoporosis and other bone disease associated with bone loss. 
Clinical trials have consistently shown that fluoride can increase spinal bone mass in a dose 
dependent manner; however, there is disagreement as to its ability to reduce vertebral 
fracture risk [3, 19]. Morphology studies in humans and animal models have found that new 
bone formed with fluoride treatment is often histologically abnormal. Woven bone rather 
lamellar bone is formed. Generalized or focal osteomalacia is also observed, indicating a 
deficiency in mineralization [24]. It is therefore proposed that the failure of fluoride to 
reduce vertebral fracture risk may be partially caused by the abnormal structure and 
compromised strength of fluoride-treated bone [3, 24]. 
  Due to fluoride’s similar size and charge to the hydroxyl ion— the normal 
component of hydroxyapatite, fluoride can substitute the hydroxyl group to form fluorapatite 
[25]. Compared to hydroxyapatite, fluoroapatite has a greater crystallinity, larger crystal size, 
and lower solubility. Moreover, fluoride can inhibit the dissolution of pre-formed 
hydroxyapatite, likely by forming a surface layer of less soluble fluoroapatite [26]. However, 
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the biological significance of these findings is not clear. No evidence has suggested that the 
formation of fluoroapatite per se alters the mechanical property of bone [21]. Therefore, the 
defective structure of fluoride-treated bone is probably caused by the cellular action of 
fluoride, rather than to its physicochemical action.  
   
5.2.2. In Vitro Effects on Osteoblasts 
  The first in vitro evidence demonstrated that fluoride (~10μM) can increase the 
proliferation and differentiation of bone-forming cells derived from chick embryonic 
calvaria [27]. Despite some negative results reported [28-31], the direct action of fluoride on 
osteoblastic proliferation and differentiation has been largely confirmed in similar or other 
osteoblast-like cell culture system [32-35]. Studies have also showed that in vitro fluoride 
treatment at similar concentrations can stimulate the proliferation and differentiation of 
osteoprogenitors (pre-osteoblasts) [34, 36], which are more sensitive to fluoride than mature 
osteoblasts [35]. It is therefore largely accepted that fluoride can enhance osteoblastic 
proliferation and activity, but the underlying mechanism has not been completely defined 
yet.  
  It appears that fluoride can enhance the Ras-activated MAP Kinase (MAPK) 
pathway and thereby increase osteoblast proliferation. Two competing models regarding the 
underlying mechanism have been proposed [3, 37]. 1) The tyrosine phosphatase hypothesis: 
fluoride directly inhibits a tyrosine phosphatase, resulting in increased tyrosine 
phosphorylation levels of signaling molecules involved in the Ras-Raf-MEK-ERK pathway 
[37-40]. This unique fluoride-sensitive tyrosine phosphatase has been recently suggested to 
be the tartrate-resistant acid phosphatase (TRAP), which is specifically expressed by 
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osteoblasts [41, 42]. 2) The G protein (guanine nucleotide binding protein) hypothesis: 
fluoride first forms a fluoroalumino complex with aluminum—fluoroaluminate. This 
complex interacts with GDP (guanosine diphosphate) to form a GTP (guanosine 
triphosphate)-like molecule, thereby activating a G protein. This leads to the stimulation of 
an unknown tyrosine kinase, which then increases the phosphorylation levels of signaling 
molecules in Ras-Raf-MEK-ERK pathway [43-48]. 
  The development of osteoclast biology in the late 1990s has provided us a great 
opportunity to study fluoride’s effects on bone cells in a context of osteoblasts and 
osteoclasts interaction. Interestingly, it has been reported that fluoride treatment of 
osteoporosis patients with Crohn’s disease can cause increased serum level of 
osteoprotegerin (OPG), an osteoblast-derived negative regulator of osteoclastogenesis [49]. 
This result indicates the effects of fluoride on bone cells may not be limited to osteoblasts and 
bone formation. 
 
5.2.3. Effects on Osteoclasts and Bone Marrow Cells 
  Based on both in vivo and in vitro data, researchers have hypothesized that fluoride 
can promote osteoblastic bone formation independent of any coupling between bone 
resorption and formation [22, 50]. Effects of fluoride on bone formation have been 
explained solely by its stimulation of osteoblasts, so fewer attempts have been made to 
address fluoride’s effects on bone resorption or cells of the osteoclastic lineage.  
  Using isolated chick or rabbit osteoclast culture system, two groups have found 
that fluoride can inhibit osteoclastic resorption at 500-1000μM and 15 mg/l /30mg/l (i.e. 
~360μM/720μM), respectively [51, 52]. Although it is tempting to interpret this as a direct 
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action of fluoride on osteoclasts, it should be noted that in these studies cells from animal 
long bones represented a mixed cell population. In fact, it was shown that after 48 hours in 
such isolated osteoclast cultures stromal cells became the major cell population [53]. 
Therefore, inhibition of fluoride on osteoclastic resorption could be indirectly mediated by 
factors released by stimulated osteoblast or other cell types [53]. Another point that needs 
to consider is the relatively high fluoride dose used in these experiments. Millimolar (mM) 
of fluoride has long been used as a potent inhibitor of enzyme function; however, the 
optimal fluoride dose to stimulate osteoblasts in vitro is between 10-100μM [38]. Although 
the therapeutic window for serum fluoride levels has not been firmly established, the widely 
quoted range is 5 -10 micromolar (μM) [19], while other ranges were also used, such as 5-15 
μM [54], ~8μM [55], and ~12μM [56]. Therefore, it is not likely that fluoride concentrations 
used in these studies and those described below is applicable to fluoride exposure seen in 
patients who may subject to fluoride therapy.  
  Studies of fluoride’s effects on bone have also been extended to bone marrow, 
where the progenitors of bone cells reside. Studies have shown that fluoride at 100-500μM 
can upregulate the expression of granulocyte-specific markers by the HL-60 (human 
promyelocytic leukemia cells) cell line or primary mouse bone marrow cells [57, 58]. The 
authors concluded that fluoride can shift the differentiation of myeloid cell line, HL-60 or 
primary bone marrow cells along the granulocytic but not the monocytic pathway, 
suggesting that fluoride may suppress the development of osteoclasts from bone marrow 
hematopoietic progenitor cells [57, 58]. However, stimulation of one differentiation 
pathway does not necessarily lead to suppression of another. Collectively, so far there is no 
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direct evidence for an inhibitory action of fluoride on osteoclasts or their precursors in bone 
marrow.    
  However, a recent publication has described a novel stimulatory action of fluoride 
on osteoclast differentiation [59]. C57BL/6J and C3H/HeJ mice—two inbred strains of 
mice widely used in the study of bone biology—were treated with fluoride in drinking 
water for three weeks (0 ppm, 50 ppm, and 100 ppm). Anabolic effects of fluoride in 
C57BL/6J mice were observed. Surprisingly, stimulation of osteoclastic lineages cells was 
observed in C3H/HeJ mice [59]. Bone marrow cells from C3H/HeJ mice showed increased 
osteoclast potential in culture in response to soluble RANKL and M-CSF with increasing in 
vivo fluoride exposure [59]. Consistently, in situ trabecular osteoclast number, osteoclast 
hematopoietic colony forming units, and serum makers for osteoclastic bone resorption 
(PTH, RANKL, and TRAP5b) were all increased dose-dependently. Moreover, serum OPG 
was decreased [59]. To date, this is the first report of a stimulatory effect of fluoride on 
osteoclasts. The underlying mechanism needs to be further determined as it will provide us 
a new perspective on fluoride effect on bone remodeling process.  
 
5.3. Chapter Summary 
  The bisphosphonate is currently considered a major class of drug for osteoporosis 
and other diseases associated with increased bone resorption. These compounds can induce 
osteoclast apoptosis. Based on their modes of action, bisphosphonates can be classified into 
two major groups. Non–nitrogen-containing bisphosphonates induce osteoclast apoptosis by 
forming toxic non-hydrolysable analogues of ATP, while nitrogen-containing 
bisphosphonates do so by inhibiting production of substrates for the prenylation of proteins 
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that are essential for osteoclast survival. Interestingly, the effects of bisphosphonates on 
osteoblast cell lineages have also been explored but with inconsistent results.  
  Fluoride is a potent anabolic agent, but its clinical application in treatment of 
osteoporosis and other bone diseases has been controversial. Fluoride’s stimulation on 
osteoblast proliferation has been well established, but the underlying mechanism is unclear. 
Moreover, little is known about its action on another important cell type involved in bone 
remodeling—osteoclasts. A recent study has revealed a stimulatory effect of fluoride on 
osteoclastogenesis. To harness the desirable action of fluoride while limiting its undesirable 
effects, we need to further understand fluoride’s effects on bone at both cellular and 
molecular levels. 
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Figure 5.1. The structure of bisphosphonate and pyrophosphate. 
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Figure 5.2. Structures of bisphosphonates classified according to their biochemical 
modes of action. Adapted from reference 4. 
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Figure 5.3. Formation of AppCp-type metabolites of simple bisphosphonates. Upper 
panel: Mechanism by which aminoacyl-tRNA synthetases catalyze formation of 
AppCp-type metabolites of bisphosphonates. In a reversible reaction, an amino acid 
condenses with ATP (Appp) to form an aminoacyl-adenylate (amino acid-AMP), releasing 
pyrophosphate (PPi) (reaction I). The aminoacyl-adenylate then condenses with a molecule 
of tRNA to form aminoacyl-tRNA (reaction II). Since non–nitrogen-containing 
bisphosphonates (pCp) resemble PPi in structure, the reverse reaction of (I) can occur with 
pCp in place of PPi, forming an analogue of ATP (AppCp). Lower panel: 
Non–nitrogen-containing bisphosphonate, clodronate, substitutes the pyrophosphate group 
in ATP to form an ATP analogue. Adapted from references 4 and 7.  
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Figure 5.4. Mechanism of action of nitrogen-containing bisphosphonates on osteoclasts. 
The mevalonate pathway is a biosynthetic pathway responsible for generating cholesterol 
and isoprenoid lipids. HMG-CoA reductase catalyzes conversion of HMG-CoA to 
mevolonate. Successive phosphorylation of mevalonate with ATP leads to formation of 
isopentenyl pyrophosphate (IPP). IPP is then isomerized to dimethylallyl pyrophosphate 
(DAMPP). Condensation of IPP and DAMPP results in formation of geranyl pyrophosphate 
(GPP). GPP then condenses with IPP to form farnesyl pyrophosphate (FPP). FPP can be 
further converted to cholesterol. Meanwhile, condensation of FPP and IPP leads to 
formation of geranylgeranyl pyrophosphate (GGPP). FPP and GGPP are substrates for 
prenylation of small GTPases, which are important for osteoclast functions and survival. 
Farnesyl pyrophosphate synthase (FPPS) catalyzes sequential condensation of IPP with 
DAMAP and GPP. Nitrogen-containing bisphosphonates act as substrate analogues for GPP 
and compete with GPP for FPPS binding, leading to competitive inhibition of FPPS. 
Therefore, by inhibiting FPPS, nitrogen-containing bisphosphonates block synthesis of FPP 
and GGPP and subsequent prenylation of small GTPase proteins, leading to osteoclast 
apoptosis. Adapted from references 4 and 7.  
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